Mary Barrett

TL;DR: CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC, and data confirm that CRPC commonly remains dependent on ligand-activated AR signaling.

TL;DR: Lexatumumab was safe and well tolerated at doses up to and including 10 mg/kg every 21 days and was associated with sustained stable disease in several patients, and consistent with a two-compartment model with first-order elimination from the central compartment.

TL;DR: A phase I trial to evaluate the safety and tolerability of A administered once daily at 250, 500, 750, 1,000 and 2,000 mg to chemotherapy-naive CRPC p to investigate secondary resistance due to activation of a promiscuous AR by raised precursor steroids upstream of CYP17.